世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

心臓病用幹細胞市場(アプリケーション:心不全、心筋梗塞、重症四肢虚血、その他;Source:自己由来と同種由来)-世界の産業分析、サイズ、シェア、成長、トレンド、予測、2023-2031年


Cardiology Stem Cells Market (Application: Heart Failure, Myocardial Infarction, Critical Limb Ischemia, and Others; Source: Autologous and Allogenic) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

心臓病用幹細胞市場 - レポートの範囲 TMRの調査レポート「世界の心臓病用幹細胞市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向や... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Transparency Market Research
トランスペアレンシーマーケットリサーチ
2023年3月2日 US$5,795
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
160 英語

 

サマリー

心臓病用幹細胞市場 - レポートの範囲
TMRの調査レポート「世界の心臓病用幹細胞市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向や機会も調査しています。本レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの期間における世界の心臓病用幹細胞市場の収益を提供します。また、2023年から2031年までの世界の心臓病用幹細胞市場の複合年間成長率(CAGR %)を掲載しています。

本レポートは、広範な調査を経て作成されました。一次調査では、主要なオピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行いました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、心臓病用幹細胞市場を把握しました。

二次調査には、インターネットソース、政府機関、ウェブサイト、業界団体の統計データも含まれます。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界の心臓病用幹細胞市場の様々な属性を調査しました。

本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは、世界の心臓病用幹細胞市場における競争力学の変化に光を投げかけています。これらは、既存の市場関係者だけでなく、世界の心臓病用幹細胞市場への参入に関心を持つ事業者にとっても貴重なツールとなります。

本レポートは、世界の心臓病用幹細胞市場の競争環境について掘り下げています。世界の心臓病用幹細胞市場で活動する主要企業が特定され、これらの各企業は様々な属性でプロファイルされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の心臓病用幹細胞市場のプレーヤーの属性です。

世界の心臓病用幹細胞市場レポートで回答された主要な質問
- 予測期間中にすべての地域で発生した心臓病学的幹細胞の売上高/収益はどのくらいですか?
- 世界の心臓病用幹細胞市場におけるビジネスチャンスは何か?
- 市場における主な促進要因、阻害要因、機会、脅威は何か?
- 予測期間中に最も速いCAGRで拡大するのはどの地域市場か?
- 2031年に世界で最も高い収益を上げると予測されるセグメントは?
- 予測期間中に最も高いCAGRで拡大すると予測されるセグメントはどこか?
- 世界市場で事業展開している各社の市場ポジションは?

心臓病用幹細胞市場 - 研究目的と研究アプローチ
世界の心臓病用幹細胞市場に関する包括的なレポートは、概要から始まり、研究の範囲と目的について説明します。本調査の目的、市場で活動する主要ベンダーや流通業者、製品の承認に関する規制シナリオについて詳しく解説しています。

読みやすさを考慮し、本レポートは章立てでまとめられ、各セクションはより小さなものに分割されています。本レポートは、グラフと表が適切に配置された包括的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴えかけています。また、過去と予測期間終了時の主要セグメントの市場シェアを比較することも可能です。

本レポートでは、世界の心臓病用幹細胞市場を製品、エンドユーザー、地域の観点から分析しています。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントごとの市場シェアを掲載しています。このような貴重な洞察により、市場関係者は、世界の心臓病用幹細胞市場への投資について、情報に基づいたビジネス上の意思決定を行うことができます。

ページTOPに戻る


目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiology Stem Cells Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Cardiology Stem Cells Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
    5.1. Key Mergers & Acquisitions
    5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
    5.3. Pipeline Analysis
    5.4. Disease Prevalence & Incidence Rate globally with key countries
6. Global Cardiology Stem Cells Market Analysis and Forecast, by Type of Cell
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Type of Cell, 2017-2031
        6.3.1. Embryonic Stem Cells
        6.3.2. Adult Stem Cells
        6.3.3. Induced Pluripotent Stem Cells
        6.3.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    6.4. Market Attractiveness Analysis, by Type of Cell
7. Global Cardiology Stem Cells Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Application, 2017-2031
        7.3.1. Heart Failure
        7.3.2. Myocardial Infarction
        7.3.3. Critical Limb Ischemia
        7.3.4. Others
    7.4. Market Attractiveness Analysis, by Application
8. Global Cardiology Stem Cells Market Analysis and Forecast, by Source
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Source, 2017-2031
        8.3.1. Autologous
        8.3.2. Allogenic
    8.4. Market Attractiveness Analysis, by Source
9. Global Cardiology Stem Cells Market Analysis and Forecast, by End-user
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by End-user, 2017-2031
        9.3.1. Pharmaceutical & Biotechnology Companies
        9.3.2. Hospitals & Cell Banks
        9.3.3. Academic & Research Institutes
    9.4. Market Attractiveness Analysis, by End-user
10. Global Cardiology Stem Cells Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness Analysis, by Region
11. North America Cardiology Stem Cells Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Type of Cell, 2017-2031
        11.2.1. Embryonic Stem Cells
        11.2.2. Adult Stem Cells
        11.2.3. Induced Pluripotent Stem Cells
        11.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    11.3. Market Value Forecast, by Application, 2017-2031
        11.3.1. Heart Failure
        11.3.2. Myocardial Infarction
        11.3.3. Critical Limb Ischemia
        11.3.4. Others
    11.4. Market Value Forecast, by Source, 2017-2031
        11.4.1. Autologous
        11.4.2. Allogenic
    11.5. Market Value Forecast, by End-user, 2017-2031
        11.5.1. Pharmaceutical & Biotechnology Companies
        11.5.2. Hospitals & Cell Banks
        11.5.3. Academic & Research Institutes
    11.6. Market Value Forecast, by Country, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Type of Cell
        11.7.2. By Application
        11.7.3. By Source
        11.7.4. By End-user
        11.7.5. By Country
12. Europe Cardiology Stem Cells Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Type of Cell, 2017-2031
        12.2.1. Embryonic Stem Cells
        12.2.2. Adult Stem Cells
        12.2.3. Induced Pluripotent Stem Cells
        12.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    12.3. Market Value Forecast, by Application, 2017-2031
        12.3.1. Heart Failure
        12.3.2. Myocardial Infarction
        12.3.3. Critical Limb Ischemia
        12.3.4. Others
    12.4. Market Value Forecast, by Source, 2017-2031
        12.4.1. Autologous
        12.4.2. Allogenic
    12.5. Market Value Forecast, by End-user, 2017-2031
        12.5.1. Pharmaceutical & Biotechnology Companies
        12.5.2. Hospitals & Cell Banks
        12.5.3. Academic & Research Institutes
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Type of Cell
        12.7.2. By Application
        12.7.3. By Source
        12.7.4. By End-user
        12.7.5. By Country/Sub-region
13. Asia Pacific Cardiology Stem Cells Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Type of Cell, 2017-2031
        13.2.1. Embryonic Stem Cells
        13.2.2. Adult Stem Cells
        13.2.3. Induced Pluripotent Stem Cells
        13.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    13.3. Market Value Forecast, by Application, 2017-2031
        13.3.1. Heart Failure
        13.3.2. Myocardial Infarction
        13.3.3. Critical Limb Ischemia
        13.3.4. Others
    13.4. Market Value Forecast, by Source, 2017-2031
        13.4.1. Autologous
        13.4.2. Allogenic
    13.5. Market Value Forecast, by End-user, 2017-2031
        13.5.1. Pharmaceutical & Biotechnology Companies
        13.5.2. Hospitals & Cell Banks
        13.5.3. Academic & Research Institutes
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. Japan
        13.6.2. China
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Type of Cell
        13.7.2. By Application
        13.7.3. By Source
        13.7.4. By End-user
        13.7.5. By Country/Sub-region
14. Latin America Cardiology Stem Cells Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Type of Cell, 2017-2031
        14.2.1. Embryonic Stem Cells
        14.2.2. Adult Stem Cells
        14.2.3. Induced Pluripotent Stem Cells
        14.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    14.3. Market Value Forecast, by Application, 2017-2031
        14.3.1. Heart Failure
        14.3.2. Myocardial Infarction
        14.3.3. Critical Limb Ischemia
        14.3.4. Others
    14.4. Market Value Forecast, by Source, 2017-2031
        14.4.1. Autologous
        14.4.2. Allogenic
    14.5. Market Value Forecast, by End-user, 2017-2031
        14.5.1. Pharmaceutical & Biotechnology Companies
        14.5.2. Hospitals & Cell Banks
        14.5.3. Academic & Research Institutes
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Type of Cell
        14.7.2. By Application
        14.7.3. By Source
        14.7.4. By End-user
        14.7.5. By Country/Sub-region
15. Middle East & Africa Cardiology Stem Cells Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Type of Cell, 2017-2031
        15.2.1. Embryonic Stem Cells
        15.2.2. Adult Stem Cells
        15.2.3. Induced Pluripotent Stem Cells
        15.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    15.3. Market Value Forecast, by Application, 2017-2031
        15.3.1. Heart Failure
        15.3.2. Myocardial Infarction
        15.3.3. Critical Limb Ischemia
        15.3.4. Others
    15.4. Market Value Forecast, by Source, 2017-2031
        15.4.1. Autologous
        15.4.2. Allogenic
    15.5. Market Value Forecast, by End-user, 2017-2031
        15.5.1. Pharmaceutical & Biotechnology Companies
        15.5.2. Hospitals & Cell Banks
        15.5.3. Academic & Research Institutes
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Type of Cell
        15.7.2. By Application
        15.7.3. By Source
        15.7.4. By End-user
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player - Competition Matrix (By Tier and Size of companies)
    16.2. Market Share Analysis By Company (2022)
    16.3. Company Profiles
        16.3.1. Astellas Pharma, Inc.
            16.3.1.1. Company Overview
            16.3.1.2. Product Portfolio
            16.3.1.3. SWOT Analysis
            16.3.1.4. Strategic Overview
        16.3.2. STEMCELL Technologies
            16.3.2.1. Company Overview
            16.3.2.2. Product Portfolio
            16.3.2.3. SWOT Analysis
            16.3.2.4. Strategic Overview
        16.3.3. Cellular Engineering Technologies
            16.3.3.1. Company Overview
            16.3.3.2. Product Portfolio
            16.3.3.3. SWOT Analysis
            16.3.3.4. Strategic Overview
        16.3.4. BioTimes, Inc.
            16.3.4.1. Company Overview
            16.3.4.2. Product Portfolio
            16.3.4.3. SWOT Analysis
            16.3.4.4. Strategic Overview
        16.3.5. Takara Bio, Inc.
            16.3.5.1. Company Overview
            16.3.5.2. Product Portfolio
            16.3.5.3. SWOT Analysis
            16.3.5.4. Strategic Overview
        16.3.6. U.S. Stem Cell, Inc.
            16.3.6.1. Company Overview
            16.3.6.2. Product Portfolio
            16.3.6.3. SWOT Analysis
            16.3.6.4. Strategic Overview
        16.3.7. BrainStorm Cell Limited
            16.3.7.1. Company Overview
            16.3.7.2. Product Portfolio
            16.3.7.3. SWOT Analysis
            16.3.7.4. Strategic Overview
        16.3.8. Cytori Therapeutics, Inc.
            16.3.8.1. Company Overview
            16.3.8.2. Product Portfolio
            16.3.8.3. SWOT Analysis
            16.3.8.4. Strategic Overview
        16.3.9. Bio Cardia, Inc.
            16.3.9.1. Company Overview
            16.3.9.2. Product Portfolio
            16.3.9.3. SWOT Analysis
            16.3.9.4. Strategic Overview

ページTOPに戻る



図表リスト

List of Tables

Table 01: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 02: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 03: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 04: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 05: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Region, 2017–2031

Table 06: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country, 2017–2031

Table 07: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 08: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 09: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 10: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 11: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-Region, 2017–2031

Table 12: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 13: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 14: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 15: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 16: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 18: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 19: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 20: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 21: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 23: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 24: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 25: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 26: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 27: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 28: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 29: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 30: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

 

ページTOPに戻る


 

Summary

Cardiology Stem Cells Market – Scope of Report
TMR’s report on the global cardiology stem cells market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cardiology stem cells market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cardiology stem cells market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cardiology stem cells market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cardiology stem cells market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cardiology stem cells market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cardiology stem cells market.

The report delves into the competitive landscape of the global cardiology stem cells market. Key players operating in the global cardiology stem cells market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cardiology stem cells market profiled in this report.

Key Questions Answered in Global Cardiology Stem Cells Market Report
• What is the sales/revenue generated by cardiology stem cells across all regions during the forecast period?
• What are the opportunities in the global cardiology stem cells market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Cardiology Stem Cells Market – Research Objectives and Research Approach
The comprehensive report on the global cardiology stem cells market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cardiology stem cells market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cardiology stem cells market.



ページTOPに戻る


Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiology Stem Cells Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Cardiology Stem Cells Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
    5.1. Key Mergers & Acquisitions
    5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
    5.3. Pipeline Analysis
    5.4. Disease Prevalence & Incidence Rate globally with key countries
6. Global Cardiology Stem Cells Market Analysis and Forecast, by Type of Cell
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Type of Cell, 2017-2031
        6.3.1. Embryonic Stem Cells
        6.3.2. Adult Stem Cells
        6.3.3. Induced Pluripotent Stem Cells
        6.3.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    6.4. Market Attractiveness Analysis, by Type of Cell
7. Global Cardiology Stem Cells Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Application, 2017-2031
        7.3.1. Heart Failure
        7.3.2. Myocardial Infarction
        7.3.3. Critical Limb Ischemia
        7.3.4. Others
    7.4. Market Attractiveness Analysis, by Application
8. Global Cardiology Stem Cells Market Analysis and Forecast, by Source
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Source, 2017-2031
        8.3.1. Autologous
        8.3.2. Allogenic
    8.4. Market Attractiveness Analysis, by Source
9. Global Cardiology Stem Cells Market Analysis and Forecast, by End-user
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by End-user, 2017-2031
        9.3.1. Pharmaceutical & Biotechnology Companies
        9.3.2. Hospitals & Cell Banks
        9.3.3. Academic & Research Institutes
    9.4. Market Attractiveness Analysis, by End-user
10. Global Cardiology Stem Cells Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness Analysis, by Region
11. North America Cardiology Stem Cells Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Type of Cell, 2017-2031
        11.2.1. Embryonic Stem Cells
        11.2.2. Adult Stem Cells
        11.2.3. Induced Pluripotent Stem Cells
        11.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    11.3. Market Value Forecast, by Application, 2017-2031
        11.3.1. Heart Failure
        11.3.2. Myocardial Infarction
        11.3.3. Critical Limb Ischemia
        11.3.4. Others
    11.4. Market Value Forecast, by Source, 2017-2031
        11.4.1. Autologous
        11.4.2. Allogenic
    11.5. Market Value Forecast, by End-user, 2017-2031
        11.5.1. Pharmaceutical & Biotechnology Companies
        11.5.2. Hospitals & Cell Banks
        11.5.3. Academic & Research Institutes
    11.6. Market Value Forecast, by Country, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Type of Cell
        11.7.2. By Application
        11.7.3. By Source
        11.7.4. By End-user
        11.7.5. By Country
12. Europe Cardiology Stem Cells Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Type of Cell, 2017-2031
        12.2.1. Embryonic Stem Cells
        12.2.2. Adult Stem Cells
        12.2.3. Induced Pluripotent Stem Cells
        12.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    12.3. Market Value Forecast, by Application, 2017-2031
        12.3.1. Heart Failure
        12.3.2. Myocardial Infarction
        12.3.3. Critical Limb Ischemia
        12.3.4. Others
    12.4. Market Value Forecast, by Source, 2017-2031
        12.4.1. Autologous
        12.4.2. Allogenic
    12.5. Market Value Forecast, by End-user, 2017-2031
        12.5.1. Pharmaceutical & Biotechnology Companies
        12.5.2. Hospitals & Cell Banks
        12.5.3. Academic & Research Institutes
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Type of Cell
        12.7.2. By Application
        12.7.3. By Source
        12.7.4. By End-user
        12.7.5. By Country/Sub-region
13. Asia Pacific Cardiology Stem Cells Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Type of Cell, 2017-2031
        13.2.1. Embryonic Stem Cells
        13.2.2. Adult Stem Cells
        13.2.3. Induced Pluripotent Stem Cells
        13.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    13.3. Market Value Forecast, by Application, 2017-2031
        13.3.1. Heart Failure
        13.3.2. Myocardial Infarction
        13.3.3. Critical Limb Ischemia
        13.3.4. Others
    13.4. Market Value Forecast, by Source, 2017-2031
        13.4.1. Autologous
        13.4.2. Allogenic
    13.5. Market Value Forecast, by End-user, 2017-2031
        13.5.1. Pharmaceutical & Biotechnology Companies
        13.5.2. Hospitals & Cell Banks
        13.5.3. Academic & Research Institutes
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. Japan
        13.6.2. China
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Type of Cell
        13.7.2. By Application
        13.7.3. By Source
        13.7.4. By End-user
        13.7.5. By Country/Sub-region
14. Latin America Cardiology Stem Cells Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Type of Cell, 2017-2031
        14.2.1. Embryonic Stem Cells
        14.2.2. Adult Stem Cells
        14.2.3. Induced Pluripotent Stem Cells
        14.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    14.3. Market Value Forecast, by Application, 2017-2031
        14.3.1. Heart Failure
        14.3.2. Myocardial Infarction
        14.3.3. Critical Limb Ischemia
        14.3.4. Others
    14.4. Market Value Forecast, by Source, 2017-2031
        14.4.1. Autologous
        14.4.2. Allogenic
    14.5. Market Value Forecast, by End-user, 2017-2031
        14.5.1. Pharmaceutical & Biotechnology Companies
        14.5.2. Hospitals & Cell Banks
        14.5.3. Academic & Research Institutes
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Type of Cell
        14.7.2. By Application
        14.7.3. By Source
        14.7.4. By End-user
        14.7.5. By Country/Sub-region
15. Middle East & Africa Cardiology Stem Cells Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Type of Cell, 2017-2031
        15.2.1. Embryonic Stem Cells
        15.2.2. Adult Stem Cells
        15.2.3. Induced Pluripotent Stem Cells
        15.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    15.3. Market Value Forecast, by Application, 2017-2031
        15.3.1. Heart Failure
        15.3.2. Myocardial Infarction
        15.3.3. Critical Limb Ischemia
        15.3.4. Others
    15.4. Market Value Forecast, by Source, 2017-2031
        15.4.1. Autologous
        15.4.2. Allogenic
    15.5. Market Value Forecast, by End-user, 2017-2031
        15.5.1. Pharmaceutical & Biotechnology Companies
        15.5.2. Hospitals & Cell Banks
        15.5.3. Academic & Research Institutes
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Type of Cell
        15.7.2. By Application
        15.7.3. By Source
        15.7.4. By End-user
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player - Competition Matrix (By Tier and Size of companies)
    16.2. Market Share Analysis By Company (2022)
    16.3. Company Profiles
        16.3.1. Astellas Pharma, Inc.
            16.3.1.1. Company Overview
            16.3.1.2. Product Portfolio
            16.3.1.3. SWOT Analysis
            16.3.1.4. Strategic Overview
        16.3.2. STEMCELL Technologies
            16.3.2.1. Company Overview
            16.3.2.2. Product Portfolio
            16.3.2.3. SWOT Analysis
            16.3.2.4. Strategic Overview
        16.3.3. Cellular Engineering Technologies
            16.3.3.1. Company Overview
            16.3.3.2. Product Portfolio
            16.3.3.3. SWOT Analysis
            16.3.3.4. Strategic Overview
        16.3.4. BioTimes, Inc.
            16.3.4.1. Company Overview
            16.3.4.2. Product Portfolio
            16.3.4.3. SWOT Analysis
            16.3.4.4. Strategic Overview
        16.3.5. Takara Bio, Inc.
            16.3.5.1. Company Overview
            16.3.5.2. Product Portfolio
            16.3.5.3. SWOT Analysis
            16.3.5.4. Strategic Overview
        16.3.6. U.S. Stem Cell, Inc.
            16.3.6.1. Company Overview
            16.3.6.2. Product Portfolio
            16.3.6.3. SWOT Analysis
            16.3.6.4. Strategic Overview
        16.3.7. BrainStorm Cell Limited
            16.3.7.1. Company Overview
            16.3.7.2. Product Portfolio
            16.3.7.3. SWOT Analysis
            16.3.7.4. Strategic Overview
        16.3.8. Cytori Therapeutics, Inc.
            16.3.8.1. Company Overview
            16.3.8.2. Product Portfolio
            16.3.8.3. SWOT Analysis
            16.3.8.4. Strategic Overview
        16.3.9. Bio Cardia, Inc.
            16.3.9.1. Company Overview
            16.3.9.2. Product Portfolio
            16.3.9.3. SWOT Analysis
            16.3.9.4. Strategic Overview

ページTOPに戻る



List of Tables/Graphs

List of Tables

Table 01: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 02: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 03: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 04: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 05: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Region, 2017–2031

Table 06: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country, 2017–2031

Table 07: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 08: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 09: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 10: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 11: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-Region, 2017–2031

Table 12: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 13: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 14: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 15: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 16: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 18: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 19: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 20: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 21: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 23: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 24: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 25: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 26: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 27: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031

Table 28: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031

Table 29: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031

Table 30: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

Transparency Market Research社の医療分野での最新刊レポート

本レポートと同じKEY WORD(cardiology)の最新刊レポート


よくあるご質問


Transparency Market Research社はどのような調査会社ですか?


トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/18 10:27

154.74 円

162.88 円

199.42 円

ページTOPに戻る